Skip to main content
. Author manuscript; available in PMC: 2015 Jan 22.
Published in final edited form as: J Allergy Clin Immunol. 2013 Jun 20;132(4):906–11.e1-4. doi: 10.1016/j.jaci.2013.04.056

Figure 3.

Figure 3

Sensitivity measurements using LTC4 secretion as the outcome. LTC4 was measured in the same supernatants as used to measure histamine release. The data shows only subjects treated with omalizumab (n=7) and for which data was available at each of the 3 time points (baseline, 6–8 weeks, 12 weeks).